Laboratory studies show that Merck & Co's experimental oral Covid-19 antiviral drug, molnupiravir, is likely to be effective against known variants of the coronavirus, the company said on Wednesday.

They said this includes the dominant, highly transmissible Delta.

Since molnupiravir does not target the spike protein of the virus - the target of all current Covid-19 vaccines...